Other formats:
BibTeX
LaTeX
RIS
@article{2291648,
author = {Rychlíčková, Jitka and Kubickova, Vendula and Suk, Pavel and Urbanek, Karel},
article_location = {BASEL},
article_number = {3},
doi = {http://dx.doi.org/10.3390/antibiotics12030437},
keywords = {colistin; quantification methods; drug stability; pharmacokinetics; drug monitoring},
language = {eng},
issn = {2079-6382},
journal = {Antibiotics-Basel},
title = {Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review},
url = {https://www.mdpi.com/2079-6382/12/3/437},
volume = {12},
year = {2023}
}
TY - JOUR
ID - 2291648
AU - Rychlíčková, Jitka - Kubickova, Vendula - Suk, Pavel - Urbanek, Karel
PY - 2023
TI - Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review
JF - Antibiotics-Basel
VL - 12
IS - 3
SP - 1-17
EP - 1-17
PB - MDPI
SN - 20796382
KW - colistin
KW - quantification methods
KW - drug stability
KW - pharmacokinetics
KW - drug monitoring
UR - https://www.mdpi.com/2079-6382/12/3/437
N2 - The emerging resistance of Gram-negative bacteria is a growing problem worldwide. Together with the financial cost, limited efficacy, and local unavailability of newer antibiotics or their combinations, it has led to the reintroduction of colistin as a therapeutic alternative. Despite its protracted development and availability on the market, there is now a complex maze of questions surrounding colistin with a more or less straightforward relationship to its safety and efficacy. This review aims to offer a way to navigate this maze. We focus on summarizing the available literature regarding the use of colistin in critically ill patients, particularly on stability, pharmacokinetics, methods for determining plasma concentrations, and therapeutic drug monitoring benefits and limitations. Based on these data, we then highlight the main gaps in the available information and help define directions for future research on this drug. The first gap is the lack of data on the stability of intravenous and nebulization solutions at clinically relevant concentrations and under external conditions corresponding to clinical practice. Furthermore, pharmacokinetic-pharmacodynamic parameters should be validated using standardized dosing, including a loading dose. Based on the pharmacokinetic data obtained, a population model for critically ill patients should be developed. Finally, the interference of colistin with extracorporeal methods should be quantified.
ER -
RYCHLÍČKOVÁ, Jitka, Vendula KUBICKOVA, Pavel SUK and Karel URBANEK. Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review. \textit{Antibiotics-Basel}. BASEL: MDPI, 2023, vol.~12, No~3, p.~1-17. ISSN~2079-6382. Available from: https://dx.doi.org/10.3390/antibiotics12030437.
|
